{
  "slug": "dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap",
  "url": "https://reports.brox.ai/insights/dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap",
  "title": "Oral JAK inhibitor or biologic: 88.9% of US dermatologists start a pill-seeking eczema patient on the JAK, and only a $150 a month gap tips most to the biologic",
  "question": "What makes a dermatologist choose a JAK inhibitor over a biologic, and what makes them avoid it?",
  "answer": "88.9% of US dermatologists on the Brox panel would start a healthy 35-year-old with moderate-to-severe eczema who asks for a pill on an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month, falling to 81.7% at a $30 monthly gap, 69.0% at $75 and 46.8% at $150 (n=126, November 2026).",
  "fielded_at": "2026-11-02",
  "published_at": "2026-11-02",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "US dermatologists",
    "country": "US",
    "n": 126
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "For a healthy 35-year-old with moderate-to-severe eczema who dislikes injections and asks for a pill, 88.9% of US dermatologists would start an oral JAK inhibitor rather than an injectable biologic when both cost the patient $0 a month; 81.7% still would when the JAK costs $30 a month more, 69.0% at $75 more and 46.8% at $150 more.",
      "value": 88.9,
      "unit": "%",
      "base": 126,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "65.1% name the boxed safety warning as the main thing that would make them hold back from an oral JAK inhibitor for a patient who asks for a pill, against 12.7% for insurance and prior authorization hurdles, 7.1% for less long-term experience and 6.3% for routine blood test monitoring; 8.7% say nothing would hold them back.",
      "value": 65.1,
      "unit": "%",
      "base": 126,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "Of the 82 dermatologists who name the boxed warning as their main brake, 86.6% (71 of 82) would still start this low-risk patient on the oral JAK inhibitor when both options cost $0.",
      "value": 86.6,
      "unit": "%",
      "base": 82,
      "segment": "Dermatologists naming the boxed safety warning as the main brake"
    },
    {
      "anchor": "f4",
      "claim": "39 of the 59 dermatologists who would still start the oral JAK inhibitor at $150 a month more say in their answer that copay cards or manufacturer assistance would bring that cost down, so the top rung measures belief in assistance as much as tolerance of the price.",
      "value": 39,
      "unit": "count",
      "base": 59,
      "segment": "Dermatologists still choosing the oral JAK at a $150 monthly gap"
    }
  ],
  "tabulation": [
    {
      "question": "q1",
      "option": "Yes",
      "count": 126,
      "pct": 98.4,
      "base": 128
    },
    {
      "question": "q1",
      "option": "No",
      "count": 2,
      "pct": 1.6,
      "base": 128
    },
    {
      "question": "q2",
      "option": "An oral JAK inhibitor",
      "count": 112,
      "pct": 88.9,
      "base": 126
    },
    {
      "question": "q2",
      "option": "An injectable biologic",
      "count": 14,
      "pct": 11.1,
      "base": 126
    },
    {
      "question": "q3",
      "option": "An oral JAK inhibitor",
      "count": 103,
      "pct": 81.7,
      "base": 126
    },
    {
      "question": "q3",
      "option": "An injectable biologic",
      "count": 23,
      "pct": 18.3,
      "base": 126
    },
    {
      "question": "q4",
      "option": "An oral JAK inhibitor",
      "count": 87,
      "pct": 69,
      "base": 126
    },
    {
      "question": "q4",
      "option": "An injectable biologic",
      "count": 39,
      "pct": 31,
      "base": 126
    },
    {
      "question": "q5",
      "option": "An oral JAK inhibitor",
      "count": 59,
      "pct": 46.8,
      "base": 126
    },
    {
      "question": "q5",
      "option": "An injectable biologic",
      "count": 67,
      "pct": 53.2,
      "base": 126
    },
    {
      "question": "q6",
      "option": "The boxed safety warning",
      "count": 82,
      "pct": 65.1,
      "base": 126
    },
    {
      "question": "q6",
      "option": "The routine blood test monitoring",
      "count": 8,
      "pct": 6.3,
      "base": 126
    },
    {
      "question": "q6",
      "option": "Insurance and prior authorisation hurdles",
      "count": 16,
      "pct": 12.7,
      "base": 126
    },
    {
      "question": "q6",
      "option": "Less long-term experience than with biologics",
      "count": 9,
      "pct": 7.1,
      "base": 126
    },
    {
      "question": "q6",
      "option": "Nothing would make me hold back",
      "count": 11,
      "pct": 8.7,
      "base": 126
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap.csv",
    "json": "https://reports.brox.ai/insights/dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap.json",
    "markdown": "https://reports.brox.ai/insights/dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap.md",
    "html": "https://reports.brox.ai/insights/dermatologists-give-a-pill-seeking-eczema-patient-an-oral-jak-until-a-150-a-month-gap"
  }
}
